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ABSTRACT
Objectives: Our purpose was to assess the clinical
data, predictors of mortality and acute exacerbation
(AE) in combined pulmonary ﬁbrosis and emphysema
(CPFE) patients.
Design: Single-centre retrospective cohort study.
Setting: Teaching hospital in Japan.
Participants: We identiﬁed 93 CPFE patients with high-
resolution computed tomographic (HRCT) through
multidisciplinary discussion. Patients who had
connective tissue disease, drug-associated interstitial
lung disease and occupationally related interstitial lung
disease, such as asbestosis and silicosis, were excluded.
Interventions: There were no interventions.
Methods: Medical records and HRCT scans from
January 2002 through December 2007 were reviewed
retrospectively at our hospital. Ninety-three patients
had CPFE.
Results: The mean age of CPFE patients was 74 years.
Idiopathic pulmonary ﬁbrosis and non-speciﬁc
interstitial pneumonia were observed as distinct HRCT
patterns. Forty-two patients showed ﬁnger clubbing.
Mean serum Krebs von den Lungen-6 (KL-6) and per
cent predicted forced vital capacity (%FVC) were
1089 IU/l, 63.86%, respectively. Twenty-two patients
developed AE during observation period. Baseline KL-6
was a strong predictor of AE (OR¼1.0016, p¼0.009).
Finger clubbing (HR¼2.2620, p¼0.015) and per cent
predicted forced expiratory volume in one second/%
FVC more than 1.2 (HR¼1.9259, p¼0.048) were
independent predictors of mortality in CPFE.
Conclusions: Baseline serum KL-6 was a useful
predictor of AE (cut-off ¼1050, receiver operator
characteristic curve: 0.7720), which occurred in 24%
(22/93) of the CPFE patients. Finger clubbing and per
cent predicted forced expiratory volume in one second/
%FVC more than 1.2 were independent predictors of
mortality.
Combined pulmonary ﬁbrosis and emphy-
sema (CPFE) has been recognised as
a unique entity that is characterised by upper
lobe emphysema and lower lobe ﬁbrosis.
1
Emphysema is sometimes recognized in the
setting of idiopathic pulmonary ﬁbrosis (IPF)
and usually occurs with elevated lung
volume, and patients with both emphysema
and ﬁbrosis (CPFE) usually have elevated
lung volumes
23compared with patients with
IPF alone. In CPFE, lung volume is preserved
in many patients, even in those at advanced
stages, because supervening ﬁbrosis offsets
the effect of emphysema.
3e5 CPFE patients
also more often have pulmonary arterial
hypertension (PAH).
6 PAH has been shown
to be a signiﬁcant prognostic indicator for
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ARTICLE SUMMARY
Article focus
- CPFE has recently been recognised as a new
entity. Prognosis is often poor, and pulmonary
hypertension is common. There is little informa-
tion on clinical parameters and predictors of
mortality.
- What is the most useful clinical predictor of
mortality in CPFE?
- What is the most informative physiologic
predictor of mortality in CPFE?
- What is the most sensitive clinical predictor of AE
in CPFE?
- The study aim was to investigate non-invasive
predictors of mortality in CPFE.
Key messages
- From a clinical point of view, ﬁnger clubbing is
useful predictor of mortality in CPFE. In addition,
ratio of %FEV1 and %FVC more than 1.2 were
independent predictors of mortality in patients
with CPFE too. Prediction of prognosis of these
patients by minimally invasive methods may be
quite useful.
Strengths and limitations of this study
- This study’s strength was the deﬁnition of non-
invasive, easily obtainable clinical and physio-
logical measures of prognosis in CPFE. The
major limitation of the study is the single-centre
retrospective design.
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78and chronic obstructive pulmonary disease.
9
In patients with lung cancer, CPFE is more prevalent
than ﬁbrosis.
10 Recently, CPFE syndrome has been
individualised, partly on the basis of distinct character-
istics observed by high-resolution computed tomography
(HRCT) of the chest.
11
There is very little information on predictors of
mortality for CPFE.
1 12 Patients with CPFE often have
severe dyspnoea and poor cardiopulmonary reserve,
13 14
and many patients cannot tolerate invasive procedures
such as video-assisted thoracoscopic surgery.
Thus, the objective of the present study was to deter-
mine the predictors of acute exacerbation (AE) and
mortality in CPFE patients using non-invasive methods.
METHODS
Study population and HRCT assessment
We retrospectively investigated our medical records and
HRCT scans from Okinawa Chubu Hospital, Okinawa,
Japan, from 1 January 2002 through 31 December 2007.
During this period, we had 319 interstitial lung disease
(ILD) patients. Eligible patients were men and women
aged 18 years or older with a proven diagnosis of IPF or
non-speciﬁc interstitial pneumonia (NSIP) according to
the American Thoracic Society/European Respiratory
Society (ATS/ERS) statement.
15 Among all ILD
patients, we identiﬁed 93 CPFE patients through
multidisciplinary discussion including our pulmonolo-
gists and radiologists. We excluded patients if (1) they
were without HRCT imaging, (2) had connective tissue
disease, (3) had drug-associated ILD and (4) had
occupationally related ILD, such as asbestosis and sili-
cosis. Demographic and clinical data were obtained,
including age, gender, smoking history, dyspnoea
duration, comorbidity, crackles, clubbing, Krebs von
den Lungen-6 (KL-6) levels and ultrasound cardiog-
raphy ﬁndings. In terms of PAH, we estimated with
ultrasound cardiography. We also checked physiological
data including forced expiratory volume in one second
(FEV1), per cent predicted forced vital capacity volume
in one second (%FEV1), forced vital capacity (FVC) and
per cent predicted forced vital capacity (%FVC). We
only included pulmonary function data determined
within 6 months of the date of HRCT.
The HRCT scan imaging patterns were evaluated
according to the ATS/ERS criteria.
15 We diagnosed IPF
patients using the new ATS/ERS and Japanese Respira-
tory Society/Latin America Thoracic Association
criteria.
16 Patients who met the following criteria, as
described by Cottin et al,
1 were diagnosed as having
CPFE: (1) the presence of emphysema on CT, deﬁned as
well-demarcated areas of decreased attenuation
compared with contiguous normal lung, marginated by
a very thin (<1 mm) wall or no wall and/or multiple
bullae (>1 cm) with upper zone predominance, and (2)
the presence of signiﬁcant pulmonary ﬁbrosis on CT,
deﬁned as reticular opacities with peripheral and basal
predominance, with or without traction bronchiectasis
that occurs with or without honeycombing. Regarding
AE, we deﬁned by the following criteria
17: (1) sudden
deterioration of dyspnoea within 30 days, (2) new bilat-
eral inﬁltration on chest radiograph and (3) pulmonary
infection or other known causes were excluded by
bronchoalveolar lavage. Survival time was deﬁned from
the date of HRCT to death or last observation date. The
Ethics Committee of Okinawa Chubu Hospital approved
this study protocol.
Statistical methods
Clinical data are presented as means6SDs or medians
(range), depending on distribution. Group comparisons
were made using unpaired t tests, the Wilcoxon rank
sum test, c
2 statistics and Fisher’s exact test, as appro-
priate. Logistic regression analysis was performed to
determine the relationship between clinical parameters
and AE. A Cox proportional hazards model analysis was
performed to determine the relationships between
clinical parameters, physiological indices, HRCT
imaging patterns and survival. Clinical data analyses were
performed using STATA software V.11.0 (Stata Corp).
Statistical signiﬁcance was deﬁned as a p value <0.05.
RESULTS
Patient characteristics, AE and clinical parameters
The ﬂow diagram in ﬁgure 1 shows how the patients
were identiﬁed. Ninety-three CPFE patients (76 men, 17
women) were identiﬁed between 2002 and 2007. The
mean age was 73 years, and 82% of the patients were
men. The mean time from symptoms to diagnosis was
12.68 months (0e96 months). The mean follow-up
period was 30.7 months (0e74.6 months). All patients
had histories of smoking (mean: 62 pack-years). The
mean modiﬁed Medical Research Council (mMRC)
breathlessness score was 2.5. Bibasilar ﬁne crackles were
auscultated in all patients and 42 (45%) had ﬁnger
clubbing. The baseline %FEV1 (FEV1/average %FEV1
for similar age, sex and body composition) was
70.95%, and the baseline per cent predicted FVC was
63.86%. During observation period, 67 patients (72%)
died. The clinical characteristics of both survivors and
non-survivors are summarised in table 1.
The mean partial pressures of oxygen (PaO2)a n d
carbon dioxide (PaCO2) were 63 and 43 mm Hg,
respectively. Thirty-two patients (34%) received home
oxygen therapy and 36 (39%) had PAH. The mean
systolic pulmonary arterial pressure was 62 mm Hg. CPFE
patients frequently have been reported to have lung
cancer, especially squamous cell carcinoma.
10 18 However,
in our cohort, only 12 (13%) patients developed lung
cancer.
Among the 93 patients, 22 (24%) developed AE, which
met the ATS/ERS criteria.
15 We performed univariate
analysis to determine predictors of AE. Age, mMRC
score, CT pattern and baseline serum KL-6 were identi-
ﬁed as possible predictors of AE. Logistic regression
analysis was performed for these four factors, baseline
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in the CPFE patients (OR¼1.0016, p¼0.009) (table 2).
Using receiver operator characteristic curve (ROC)
analysis, the useful KL-6 threshold was determined to be
1050 (ROC: 0.7720).
HRCT imaging and predictors of mortality
According to the ATS/ERS criteria,
15 16 the patients
were divided into those with usual interstitial pneumonia
(UIP) patterns and those with NSIP patterns. There were
68 patients in the IPF-pattern group and 25 patients in
the NSIP-pattern group. The HRCT images also showed
patterns indicating that 51 patients had paraseptal
emphysema, 28 had centrilobular emphysema and 14
had panlobular emphysema. Detailed results are
presented in (table 3).
The mean survival of CPFE patients was 30.7 months
(0.10e75.63 months) (ﬁgure 2). Patients with ﬁnger
clubbing or increased ratio of %FEV1 to %FVC showed
poor survival in CPFE patients (ﬁgures 3 and 4).
Regarding ratio of %FEV1 to %FVC, we chose 1.2 which
was most useful threshold for predictor of mortality
using ROC analysis (ROC: 0.7671). Initially, we
performed univariate analysis with a cut-off value of 0.1,
which showed that baseline KL-6, ﬁnger clubbing, PaO2
and %FEV1/%FVC >1.2 were independent predictors
of mortality. Cox proportional hazards regression anal-
ysis showed that ﬁnger clubbing (HR¼2.2620, p¼0.015)
and ratio of %FEV1 to %FVC more than 1.2
(HR¼1.9259, p¼0.048) were the strongest independent
predictors of mortality in CPFE patients at our hospital
(table 4).
DISCUSSION
Previous studies have reported a high prevalence of PAH
and lung cancer in CPFE patients.
1 10 These comorbid-
ities were associated with poor prognosis; the 1-year
survival rate for CPFE patients with PAH was only 60%.
61 1
Among these patients, high mean pulmonary arterial
pressure, high pulmonary vascular resistance, high heart
rate and low diffusing capacity for carbon monoxide
(DLco) were signiﬁcantly associated with poor outcome.
In one study, CPFE patients had a ﬁvefold higher
mortality risk (adjusted HR 5.10, 95% CI 1.75 to 14.9) in
non-malignant situations.
19 In the present study, only 12
Table 1 Patient clinical characteristics in CPFE
Survivors (n[26) Non-survivors (n[67) p Value
Age, year (mean) 73.1961.18 (57e84) 73.8367.07 (56e91) 0.5815
Male sex, % 85 81 0.6570
Pack-year 60622.0 (5e110) 64631.4 (0e180) 0.5754
mMRC scale 2.660.88 (1e4) 2.560.93 (1e4) 0.5091
Dyspnoea duration, months 11.0465.73 (0e18) 13.07614.20 (0e96) 0.4821
Clubbing, % 12 55 <0.0001
KL-6, IU/l 8526278 (505e1200) 11746725 (201e4250) 0.0413
Systolic PAP, mm Hg 45 75 <0.0001
Baseline FEV1, % 71.1468.72 (59.6e103.9) 70.8869.25 (31.4e106.3) 0.9128
Baseline FVC, % 68.5269.09 (57e99.7) 61.8969.48 (24.9e82.3) 0.0058
HOT, % 12 43 0.0035
Paraseptal emphysema, % 19 69 <0.0001
Acute exacerbation, n (%) 0 (0) 22 (32) 0.0007
%FEV1/%FVC >1.2, % 19 79 <0.0001
Cancer, % 0 18 0.1068
Cardiovascular, % 27 40 0.2339
Ejection fraction, % 58.263.90 56.965.19 0.2337
Survival time, months 50.16617.79 (26e96) 25.68621.54 (1e98) <0.0001
Data are presented as mean6SD and mean %predicted 6 SD.
CPFE, combined pulmonary ﬁbrosis and emphysema; FEV1, forced expired volume in one second; %FEV1, per cent predicted forced expired
volume in one second; FVC, forced vital capacity; HOT, Home Oxygen Therapy; IPF, idiopathic pulmonary ﬁbrosis; mMRC, modiﬁed Medical
Research Council; NSIP, non-speciﬁc interstitial pneumonia.
Figure 1 Flow diagram in CPFE patients.
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Mortality predictors in CPFEof 93 patients had lung cancer in contrast to the number
reported in a previous study.
10 Our institution is
a teaching and community hospital, and the patient
population may be different from that of a university
hospital.
The pulmonary function indices of the CPFE patients
included in the present study were rather different from
those in previous reports.
1 20 The CPFE patients in those
studies had greater preserved lung volume despite
reduced DLco, reduced transfer coefﬁcient for carbon
monoxide (Kco) and hypoxaemia. Jankowich and
Rounds
21 reported that CPFE altered physiology but had
a mortality rate similar to that of IPF. In addition, Peng
et al
22 reported similar physiology results for CPFE. In
our study, the mean per cent predicted FVC was 63.86%
and that of FEV1 was 70.95%, which showed more
restrictive impairment compared with previous cases.
This ﬁnding can be explained by the greater volume loss
of the lower lung ﬁeld due to severe ﬁbrosis rather than
by the offset effect of emphysema.
23 This ﬁnding might
also be because our cohort had less emphysema area
compared with the previously reported cases. Another
possibility is that the patients might have been in
a different phase of CPFE. Recently, Rogliani et al
24
reported the pathology of IPF and emphysema. They
evaluated 17 biopsy-proven UIP patients and found
ﬁbroblasts in areas of parenchymal destruction from
emphysema/UIP-expressed matrix metalloproteinase
(MMP)-2, MMP-9, MMP-7 and membrane type 1
(MT1)dMMP at signiﬁcantly higher levels when
compared with emphysema subjects. On the basis of this
result, similar to the ﬁndings of the study by Rogliani
et al cited above, interstitial ﬁbroblast activation could be
stimulated to a greater degree in the areas of lung
destruction in CPFE compared with emphysema alone,
as in exaggerated tissue remodelling. Therefore, some of
the CPFE patients may have had more intense ﬁbrosis,
which contributed to reduced FVC.
In the analysis of the HRCT images, the patients were
divided into two groups by UIP pattern and NSIP pattern
according to the ATS/ERS criteria.
15 16 All the UIP-
pattern patients had honeycombing, and the NSIP-
pattern patients more often had consolidation (60% vs
29%) and ground-glass opacity (100% vs 34%). These
ﬁndings were very similar to those from a recent report
on HRCT for NSIP.
25 In addition, Sumikawa et al
26
reported that traction bronchiectasis and ﬁbrosis scores
Table 2 Predictor of acute exacerbation in CPFE patients
OR (95% CI) p Value
Age 0.9691 (0.8985 to 1.0453) 0.417
mMRC scale 0.6681 (0.3538 to 1.2616) 0.214
Dyspnoea duration 0.8967 (0.8169 to 0.9844) 0.022
Baseline KL-6 1.0016 (1.0003 to 1.0027) 0.009
CT pattern 0.7612 (0.2247 to 2.5779) 0.661
CPFE, combined pulmonary ﬁbrosis and emphysema; mMRC,
modiﬁed Medical Research Council.
Table 3 HRCT imaging in CPFE patients
UIP pattern
(n[68)
NSIP pattern
(n[25)
All
(n[93)
Emphysema pattern
Paraseptal, % 57 48 55
Centrilobular, % 29 32 30
Panlobular, % 14 20 15
Fibrosis pattern
Traction
bronchiectasis, %
96 88 94
Reticulation, % 91 88 90
Honeycombing, % 100 0 73
Ground-glass
opacity, %
34 100 52
Consolidation, % 29 60 38
CPFE, combined pulmonary ﬁbrosis and emphysema; HRCT, high-
resolution computed tomography; IPF, idiopathic pulmonary
ﬁbrosis; NSIP, non-speciﬁc interstitial pneumonia; UIP, usual
interstitial pneumonia.
Figure 2 Survival curve in CPFE patients.
Figure 3 CPFE patients with clubbing show poor survival
compared with that of without clubbing.
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patients. In the present study, HRCT pattern was not an
independent prognostic predictor. CPFE patients usually
have more severe PAH, low cardiac index
6 and are
disabled,
27 which we observed in our cohort. Thus, most
CPFE patients cannot tolerate invasive procedures such
as video-assisted thoracic surgery. Therefore, we cannot
compare biopsy-proven UIP with CPFE equally.
AE is a relentlessly progressive status and is associated
with poor outcome.
28 Thus, we evaluated AE of CPFE.
During the observation period (mean: 30.7 months), 22
patients (24%) developed AE. The annual incidence of
AE is 9.4%. This ﬁnding is similar to that reported in IPF
recently.
29 Kondoh et al
30 reported that high mMRC
score, high body mass index and decline in FVC at
6 months were signiﬁcant independent risk factors for
AE-IPF. KL-6 levels in ILD patients reﬂect the overall
extent of interstitial lesions. Among the many clinical
parameters, baseline serum KL-6 was the most powerful
predictor of AE in our CPFE patients. ROC analysis
showed that the useful threshold was 1050 (ROC
¼0.7720).
Finally, we investigated the prognostic predictors of
CPFE in our cohort. FVC has been reported robust
powerful predictor of mortality in IPF patients.
31 DLco
often show variable value, so reproducibility is rather
poor. In addition when FVC is reduced, DLco cannot be
obtained with single-breath method. Therefore, we chose
%FEV1, %FVC and ratio of these value as important
indices out of pulmonary function parameters. Univariate
analysis revealed that KL-6, ﬁnger clubbing, PaO2 and
ratio of %FEV1 to %FVC were independent predictors.
Regression analysis using a Cox proportional hazards
model showed that ﬁnger clubbing and ratio of %FEV1 to
%FVC more than 1.2 were the strongest independent
predictors of mortality in CPFE at our hospital. In CPFE
patients, lung volume is usually preserved. Therefore,
absolute value of FVC or %FVC itself has been reported to
be not robust predictor of critical event. However, ratio of
%FEV1 to %FVC may be useful parameter in subgroup of
CPFE patients. In terms of different cut-off value of this
ratio, CPFE patients tend to have more mild restrictive
impairment compared with that of IPF patients. Another
interesting ﬁnding was that ﬁnger clubbing is related to
poor survival in CPFE patients. Finger clubbing usually
shows chronicity in ILD patients. However, it predicted
clinical course in CPFE patients at our cohort. So, we
insist on the importance of initial careful evalution of
physical ﬁndings in CPFE.
This time, we did not evaluate the treatment in CPFE
patients. Currently, there is no consensus on treatment
of CPFE with PAH.
32 33 This is a vital topic for future
study.
There were several limitations in our study. First, this
was a single-centre, uncontrolled design retrospective
study, which means that it is possible that important data
were not collected. Second, we did not measure the
exact areas of emphysema and ﬁbrosis. Therefore, our
cohort may have been at a different stage compared with
previous CPFE patients. Third, most of our patients
could not undergo surgical biopsy because of disability
and reduced lung function. Thus, we could not evaluate
the detailed pathology of our CPFE patients. Fourth, we
did not evaluate serial pulmonary function. Recently, du
Bois et al
34 reported that per cent predicted FVC and the
24 week change in FVC were useful predictors of
mortality in IPF. Therefore, it might be helpful to
measure serial FVC as a prognostic predictor in CPFE.
Lastly, in keeping with previous reports, our study
patients were all heavy smokers. Therefore, we could not
distinguish CPFE from smoking-related NSIP.
35
However, even considering these limitations, prediction
of prognosis using minimally invasive methods in these
patients may be quite useful.
In conclusion, CPFE patients showed poor survival in
our cohort. CPFE patients often develop AE, for which
baseline serum KL-6 was a useful predictor. Finger
clubbing and %FEV1/%FVC more than 1.2 were inde-
pendent prognostic predictors of mortality in patients
with CPFE. A multicenter study of this new entity is
warranted for further research.
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